How are BEAM strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BEAM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$437.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a BEAM strangle?

The breakeven for the BEAM strangle priced on this page is roughly $22.63 and $33.38 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BEAM market-implied 1-standard-deviation expected move is approximately 23.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current BEAM implied volatility affect this strangle?

BEAM ATM IV is at 81.70% with IV rank near 41.87%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

BEAM Strangle Strategy

BEAM (Beam Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM (Beam Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.28B, a beta of 2.26 versus the broader market, a 52-week range of 15.35-36.44, average daily share volume of 2.1M, a public-listing history dating back to 2020, approximately 393 full-time employees. These structural characteristics shape how BEAM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.26 indicates BEAM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on BEAM?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current BEAM snapshot

As of May 15, 2026, spot at $28.00, ATM IV 81.70%, IV rank 41.87%, expected move 23.42%. The strangle on BEAM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on BEAM specifically: BEAM IV at 81.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 23.42% (roughly $6.56 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BEAM expiries trade a higher absolute premium for lower per-day decay. Position sizing on BEAM should anchor to the underlying notional of $28.00 per share and to the trader's directional view on BEAM stock.

BEAM strangle setup

The BEAM strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BEAM near $28.00, the first option leg uses a $29.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BEAM chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BEAM shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$29.00	$2.40
Buy 1	Put	$27.00	$1.98

BEAM strangle risk and reward

Net Premium / Debit: -$437.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$437.50
Breakeven(s): $22.63, $33.38
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

BEAM strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on BEAM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$2,261.50
$6.20	-77.9%	+$1,642.52
$12.39	-55.8%	+$1,023.53
$18.58	-33.6%	+$404.55
$24.77	-11.5%	-$214.44
$30.96	+10.6%	-$241.58
$37.15	+32.7%	+$377.41
$43.34	+54.8%	+$996.39
$49.53	+76.9%	+$1,615.38
$55.72	+99.0%	+$2,234.36

When traders use strangle on BEAM

Strangles on BEAM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BEAM chain.

BEAM thesis for this strangle

The market-implied 1-standard-deviation range for BEAM extends from approximately $21.44 on the downside to $34.56 on the upside. A BEAM long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BEAM IV rank near 41.87% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on BEAM should anchor more to the directional view and the expected-move geometry. As a Healthcare name, BEAM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BEAM-specific events.

BEAM strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BEAM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BEAM alongside the broader basket even when BEAM-specific fundamentals are unchanged. Always rebuild the position from current BEAM chain quotes before placing a trade.

Frequently asked questions

What is a strangle on BEAM?: A strangle on BEAM is the strangle strategy applied to BEAM (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BEAM stock trading near $28.00, the strikes shown on this page are snapped to the nearest listed BEAM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are BEAM strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BEAM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$437.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a BEAM strangle?: The breakeven for the BEAM strangle priced on this page is roughly $22.63 and $33.38 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BEAM market-implied 1-standard-deviation expected move is approximately 23.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on BEAM?: Strangles on BEAM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BEAM chain.
How does current BEAM implied volatility affect this strangle?: BEAM ATM IV is at 81.70% with IV rank near 41.87%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.